Autism spectrum disorders

The developmental pipeline for drugs to treat autism spectrum disorders (ASDs) has more than doubled since April last year, and each candidate in clinical development targets a different mechanism of action. This article investigates the ASD market and provides an overview of experimental therapies.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2012-10, Vol.11 (10), p.745-746
1. Verfasser:	Nightingale, Sarah
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/436 631/378/1689/1373 Adolescent Aripiprazole Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research Child Development Disorders, Pervasive - diagnosis Child Development Disorders, Pervasive - psychology Child Development Disorders, Pervasive - therapy Child, Preschool Clinical Trials as Topic - trends Drug therapy from-the-analysts-couch Health aspects Humans Medicinal Chemistry Molecular Medicine Pervasive developmental disorders Pharmacology/Toxicology Piperazines - therapeutic use Quinolones - therapeutic use Risk factors Risperidone - therapeutic use Serotonin uptake inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The developmental pipeline for drugs to treat autism spectrum disorders (ASDs) has more than doubled since April last year, and each candidate in clinical development targets a different mechanism of action. This article investigates the ASD market and provides an overview of experimental therapies.
ISSN:	1474-1776 1474-1784
DOI:	10.1038/nrd3771